Abstract
Background: Errors involving the mix-up of tuberculin purified protein derivative (PPD) and vaccines leading to adverse reactions and unnecessary medical management have been reported previously.
Objectives: To determine the frequency of PPD-vaccine mix-ups reported to the US Vaccine Adverse Event Reporting System (VAERS) and the Adverse Event Reporting System (AERS), characterize adverse events and clusters involving mix-ups and describe reported contributory factors.
Methods: We reviewed AERS reports from 1969 to 2005 and VAERS reports from 1990 to 2005. We defined a mix-up error event as an incident in which a single patient or a cluster of patients inadvertently received vaccine instead of a PPD product or received a PPD product instead of vaccine. We defined a cluster as inadvertent administration of PPD or vaccine products to more than one patient in the same facility within 1 month.
Results: Of 115 mix-up events identified, 101 involved inadvertent administration of vaccines instead of PPD. Product confusion involved PPD and multiple vaccines. The annual number of reported mix-ups increased from an average of one event per year in the early 1990s to an average of ten events per year in the early part of this decade. More than 240 adults and children were affected and the majority reported local injection site reactions. Four individuals were hospitalized (all recovered) after receiving the wrong products. Several patients were inappropriately started on tuberculosis prophylaxis as a result of a vaccine local reaction being interpreted as a positive tuberculin skin test. Reported potential contributory factors involved both system factors (e.g. similar packaging) and human errors (e.g. failure to read label before product administration).
Conclusions: To prevent PPD-vaccine mix-ups, proper storage, handling and administration of vaccine and PPD products is necessary.
Similar content being viewed by others
Notes
1The use of trade names is for product identification purposes only and does not imply endorsement.
References
Kohn LT, Corrigan JM, Donaldson MS. To err is human: building a safer health care system. Washington, DC: National Academy Press, 1999
Barham B, Rickman L. Tuberculin substituted for terbutaline. No “tine” for error. Chest 1988 Nov; 94(5): 1120–1
Grabenstein JD, Cohen MR. Recognizing and preventing errors involving immunologic drugs. In: Cohen M, editor. Medication errors. Washington, DC: American Pharmaceutical Association, 1999: 17. 11–17. 14
Wise RP, Braun MM, Seward JF, et al. Pharmacoepidemiologic implications of erroneous varicella vaccinations in pregnancy through confusion with varicella zoster immune globulin. Pharmacoepidemiol Drug Saf 2002 Dec; 11(8): 651–4
Varricchio F. Medication errors reported to the vaccine adverse event reporting system (VAERS). Vaccine 2002 Aug 19; 20(25-26): 3049–51
Graham DR, Dan BB, Bertagnoll P, et al. Cutaneous inflammation caused by inadvertent intradermal administration of DTP instead of PPD. Am J Public Health 1981 Sep; 71(9): 1040–3
Institute for Safe Medication Practices. Hazard alert! Confusion between tetanus diphtheria toxoid (Td) and tuberculin purified protein derivative (PPD) led to unnecessary treatment. ISMP Medication Safety Alert! Acute Care Edition 2003; 8: 9
Institute for Safe Medication Practices. Hazard alert! Clusters of “positive PPD skin tests” due to intradermal injection of Td. ISMP Medication Safety Alert! Nurse Advise-ERR 2003; 1: 2
Institute for Safe Medication Practices. Aventis PPD and influenza vaccine mix-ups. ISMP Medication Safety Alert! Acute Care Edition 2004; 9: 22
Jani A. TB or not TB: analysis of a substantial positive tuberculin skin test cluster in a women's prison — Virginia, 2003. 53rd Annual Epidemic Intelligence Service (EIS) Conference; 2004 Apr 19–23; Atlanta (GA)
U.S. Pharmacopeia. USP medication error analysis: errors involving vaccines. USP Patient Safety CAPSLink [online]. Available from URL: http://www.usp.org/pdf/EN/patient-Safety/capsLink2003-10-01.pdf [Accessed 2008 Feb 12]
Virginia Division of TB Control. Errors in tuberculin skin testing administration [online]. Available from URL: http://www.vdh.virginia.gov/epidemiology/DiseasePrevention/Programs/Tuberculosis/blast/August2004.htm#TST [Accessed 2008 Feb 12]
Institute for Safe Medication Practices. Hazard alert. ISMP Medication Safety Alert! Acute Care Edition 2005 Dec 15; 10(25): 1
Centers for Disease Control and Prevention. Notice to readers: inadvertent intradermal administration of tetanus toxoid: containing vaccines instead of tuberculosis skin tests. MMWR Morb Mortal Wkly Rep 2004 Jul 30; 53(29): 662–4
Institute for Safe Medication Practices. Worth repeating: tetanus toxoid vaccines again used for PPD. ISMP Medication Safety Alert! Acute Care Edition 2004; 9: 3
US Food and Drug Administration. Mix up between Td and PPD. FDA patient safety news [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=17#8 [Accessed 2008 Feb 12]
Chang S, O'Connell K, Polder JA, et al. Errors involving mix-up of tuberculin purified protein derivative and vaccine products: TB notes no.1, 2005 [online]. Available from URL: http://www.cdc.gov/tb/notes/TBN_1_05/Errors_mix_up.htm [Accessed 2008 Feb 12]
Singleton JA, Lloyd JC, Mootrey GT, et al. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system: VAERS Working Group. Vaccine 1999 Jul 16; 17(22): 2908–17
Chen RT, Rastogi SC, Mullen JR, et al. The vaccine adverse event reporting system (VAERS). Vaccine 1994 May; 12(6): 542–50
US Food and Drug Administration. Adverse event reporting system (AERS) [online]. Available from URL: http://www.fda.gov/cder/aers/default.htm [Accessed 2008 Feb 12]
Thomson Healthcare. Integrated Index®: Aplisol (tuberculin purified protein derivative, diluted [stabilized solution]). Thomson MICROMEDEX [online]. Available from URL: http://csi.micromedex.com [Accessed 2008 Feb 12]
Thomson Healthcare. Integrated Index®: tuberculin purified protein derivative (Mantoux) Tubersol. Thomson MICROMEDEX [online]. Available from URL: http://csi.micromedex.com [Accessed 2008 Feb 12]
Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS): United States, 1991–2001. MMWR Surveill Summ 2003 Jan 24; 52(1): 1–24
Hanley K. An investigation of an increased positive tuberculin skin testing reaction rate in a deployable marine unit. Naval Med Surv Rep 2001; 4: 15–8
Guernsey BG, Ingrim NB, Hokanson JA, et al. Pharmacists' dispensing accuracy in a high-volume outpatient pharmacy service: focus on risk management. Drug Intell Clin Pharm 1983 Oct; 17(10): 742–6
Landrigan CP, Rothschild JM, Cronin JW, et al. Effect of reducing interns' work hours on serious medical errors in intensive care units. N Engl J Med 2004 Oct 28; 351(18): 1838–48
Santell JP, Hicks RW, McMeekin J, et al. Medication errors: experience of the United States Pharmacopeia (USP) MEDMARX reporting system. J Clin Pharmacol 2003 Jul; 43(7): 760–7
Leape LL, Lawthers AG, Brennan TA, et al. Preventing medical injury. QRB Qual Rev Bull 1993 May; 19(5): 144–9
Golub JE, Bur S, Cronin WA, et al. Delayed tuberculosis diagnosis and tuberculosis transmission. Int J Tuberc Lung Dis 2006 Jan; 10(1): 24–30
MacIntyre CR, Plant AJ, Hulls J, et al. High rate of transmission of tuberculosis in an office: impact of delayed diagnosis. Clin Infect Dis 1995 Nov; 21(5): 1170–4
Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005 Nov 4; 54 (RR-12): 1–81
Israel HL, Gottlieb JE, Maddrey WC. Perspective: preventive isoniazid therapy and the liver. Chest 1992 May; 101(5): 1298–301
Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection: United States, 2003. MMWR Morb Mortal Wkly Rep 2003 Aug 8; 52 (31): 735–9
Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2002 Nov 8; 51(44): 998–9
Institute for Safe Medication Practices. Your reports at work: labeling change. ISMP Medication Safety Alert! Acute Care Edition 2006; 11: 2
Institute for Safe Medication Practices. Your reports at work! Packaging change. ISMP Medication Safety Alert! Community/Ambulatory Care Edition 2007; 6: 4
US Food and Drug Administration. FDA issues bar code regulation: 25 February 2004 [online]. Available from URL: http://www.fda.gov/oc/initiatives/barcode-sadr/fs-barcode.html [Accessed 2008 Feb 12]
US Pharmacopeia. USP medication errors reporting program [online]. Available from URL: http://www.usp.org/hqi//patientSafety/mer/ [Accessed 2008 Feb 12]
Institute for Safe Medication Practices. USP-ISMP medication errors reporting program (MERP) [online]. Available from URL: https://www.ismp.org/orderforms/reporterrortoISMP.asp [Accessed 2008 Feb 12]
Acknowledgements
The authors thank the US VAERS Working Group for their dedication to the maintenance of VAERS.
The authors were full-time employees of the FDA and US CDC at the time this work was conducted and completed this work as part of their routine duties. The authors have no conflicts of interest that are directly relevant to the content of this study. Currently, Soju Chang is with the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, MD, USA; Vitali Pool is with Eli Lilly and Company, Indianapolis, IN, USA; Kathryn O'Connell is with the Division of Risk Management, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, USA; Jacquelyn A. Polder is with the Division of Global Migration and Quarantine, National Center for Infectious Diseases, Coordinating Center for Infectious Diseases, US CDC, Atlanta, GA, USA; M. Miles Braun is with the Office of Orphan Products Development, Office of the Commissioner, FDA, Rockville, MD, USA.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chang, S., Pool, V., O'Connell, K. et al. Preventable Mix-ups of Tuberculin and Vaccines. Drug-Safety 31, 1027–1033 (2008). https://doi.org/10.2165/00002018-200831110-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200831110-00007